Media, page-88

First 88 Last

Share
Profile

Follow
bioqld

537 Posts.

178

18/07/24

11:01

Post #: 74808651
Share

Originally posted by Joe007: ↑

Apologies for not getting back to you sooner.It’s always busy at Immutep. We announced this morning that we received regulatory clearance to commence our first in human trials for IMP761, our candidate for autoimmune diseases.I wish I could further elaborate on what my clinical and regulatory affairs colleagues are discussing with the regulatory agencies but at this stage I unfortunately don’t have any concrete details. Once we do have some further certainty (which we might not have until the data further matures eg PFS and OS data) we will update the market.I think it’s reasonable to assume that our team will be exploring all possible pathways to get efti registered, including priority review. The efti data shown in cohort B of TACTI-003 for CPS<1 patients, who are known not to respond well to Keytruda monotherapy, is extremely exciting and has now been recognised by Key Opinion Leaders following the ESMO Plenary presentation. However, in the meantime we are also busy preparing for the pharmacy se 3 in 1L NSCLC, which is the most significant indication for Keytruda. This indication is 8 times greater than 1L HNSCC, which is why we made the decision a while back to prioritise efti’s development in lung cancer.Our covering analysts believe that Immutep’s current valuation doesn’t fully reflect the significant opportunity we have, even just for efti in lung cancer let alone all the other indications we have been progressing efti clinical development in and the candidates that we have.Kind regards,
Regards
Deanne Miller

Expand

Thanks Joe, what a novel idea to ask them directly

IMM Price at posting: 29.0¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

What's causing the cost-of-living crisis, and how to navigate it

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t